EF Hutton Reiterates Buy on Allogene Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Allogene Therapeutics (NASDAQ:ALLO) and maintained a $15 price target.
August 04, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on Allogene Therapeutics and maintained a $15 price target.
The reiteration of a 'Buy' rating by EF Hutton indicates a positive outlook for Allogene Therapeutics. The maintained price target of $15 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100